Hillstream BioPharma Inc.: management transactions · United States · SEC (Form 4)

About Hillstream BioPharma Inc.

Hillstream BioPharma Inc. is a U.S.-based biotechnology company listed on NASDAQ in the United States (United States). For French, Belgian and Swiss investors, it should be viewed as a speculative healthcare micro-cap with a development-stage profile typical of preclinical or early clinical biopharma names. The company was originally built around the discovery and development of novel cancer therapies, with its historical operating footprint in New Jersey and repeated references in company communications to Bridgewater, New Jersey. SEC filings show that the business later became Tharimmune, Inc., while Hillstream’s legacy operations continue through a subsidiary, Hillstream Oncology, Inc. In practical terms, that means the Hillstream brand remains tied to a scientific pipeline even as the corporate structure has evolved. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1861657/000164117225009569/R9.htm?utm_source=openai)) From a business standpoint, Hillstream initially focused on ferroptosis-based oncology programs, an emerging cancer-cell death mechanism linked to iron metabolism, and later reprioritized toward HER2/HER3-targeted solid tumors. The company’s public materials describe a strategy centered on bispecific antibodies, antibody-drug conjugates (ADCs), and proprietary biologic platforms. Pipeline references include HSB-1216, HSB-3215, and platform names such as Quatramer™ and PicoKnob™. This makes Hillstream a classic innovation-driven biotech: the investment case is based on scientific optionality and the potential for differentiated assets rather than on current product sales or a mature commercial franchise. ([hillstreambio.com](https://hillstreambio.com/hillstream-biopharma-provides-business-review-with-key-pipeline-updates/?utm_source=openai)) In competitive terms, the company operates in highly crowded oncology and precision-medicine niches, where large pharmaceutical groups and many specialized biotechs compete for the same validated biological targets. Hillstream’s edge lies in the specificity of its target selection and platform approach, but the downside risk is equally high: clinical failure, funding constraints, dilution, and regulatory delays are all material. The company itself has highlighted the need for additional capital to execute on its business objectives and development timelines. ([hillstreambio.com](https://hillstreambio.com/hillstream-biopharma-announces-strategic-reprioritization-of-pipeline-to-targeting-her2-her3-solid-tumors-via-bispecific-and-adc-antibodies-and-biologics/?utm_source=openai)) Geographically, the company’s footprint is primarily U.S.-centric, with New Jersey as the main reference point in historical disclosures and press releases. For a European investor, the key takeaway is that this is a NASDAQ-listed oncology biotech in the United States with a small-cap risk profile and high sensitivity to scientific catalysts. Recent notable developments include the 2023 strategic reprioritization toward HER2/HER3, technology licensing agreements for ADC and antibody programs, and ongoing SEC Form 4 insider-transaction filings, which are closely watched in smaller listed biotech companies. ([hillstreambio.com](https://hillstreambio.com/hillstream-biopharma-announces-strategic-reprioritization-of-pipeline-to-targeting-her2-her3-solid-tumors-via-bispecific-and-adc-antibodies-and-biologics/?utm_source=openai))